

Hyperthyroidism or thyrotoxicosis?

(NOVEMBER 2008)

TO THE EDITOR: I read with interest the article by Perkins and colleagues, “A young pregnant woman with shortness of breath” on pages 788–792 of the November 2008 issue of the *Cleveland Clinic Journal of Medicine*. An incorrect meaning occurs in the article. Thyrotoxicosis is the state of symptomatic thyroid hormone excess, of both endogenous and exogenous cause. It is not synonymous with hyperthyroidism, which is the result of excessive thyroid function.

WEEKITT KITTISUPAMONGKOL, MD
Hua Chiew Hospital
Bangkok, Thailand

doi:10.3949/ccjm.76c.03001

Shingles vaccine

((JANUARY 2009))

TO THE EDITOR: In their 1-Minute Consult, Drs. Singh and Englund give a thorough review of Zostavax, the vaccine to prevent shingles.¹ Unfortunately, the information they provided on cost and reimbursement is incomplete.

As they noted, this vaccine is not covered by Medicare part B and is mandated to be covered by Medicare part D as a “prescription drug.” Furthermore, the vaccine administration charge cannot be billed to Medicare part B. Since physician offices do not bill prescription drug plans, physicians are permitted to administer the vaccine, charge the patient for the vaccine and administration, and have the patient submit the receipt to his or her prescription drug provider for reimbursement. There is no fee schedule for this vaccine, so physicians are free to charge a fee that they deem reasonable. For patients without part D, it is reasonable to ask them to call their prescription provider and inquire about coverage before vaccination, since many commercial plans will not cover the vaccine, and the \$200 or more price may be unaffordable for many.

Alternatively, physician offices may enroll with a private vendor, eDispense Vaccine Manager, at enroll.edispense.com, and submit charges for Zostavax electronically to the patient's Medicare part D provider; eDispense is contracted with most of the large part D providers. This service allows the physician to input the patient's demographics and get an immediate response, showing the patient's coverage and copayment, and allowing the physician to submit the claim electronically. There is no charge to the physician, and the reimbursement covers the cost of the vaccine, the administration cost, and a small profit. If the patient wishes to pay for the vaccine, the system can produce a receipt containing all the information needed for submission by the patient to the insurer. (Note: I have no financial or ownership interest in eDispense.com or Merck.)

Since recommending and administering Zostavax is soon to become the standard of care, the availability of these options will provide better care than the authors' recommendation that patients pick up the vaccine and transport it back to the physician's office on ice, which risks defrosting and inactivating the vaccine, or leaving patients to find a vaccine provider on their own.

RONALD HIRSCH, MD
Signature Medical Associates
Elgin, IL

■ REFERENCES

1. Singh A, Englund K. Who should receive the shingles vaccine? *Cleve Clin J Med* 2009; 76:45–48.

doi:10.3949/ccjm.76c.03002

IN REPLY: We appreciate the interest and comments of Dr Hirsch. Due to space limitations of the *Journal's* 1-Minute Consult format, we were unable to elaborate on the cost and reimbursement. Since shingles vaccine is not covered by Medicare part B, reimbursement and administration of this vaccine remains challenging, and resources like eDispense are helpful tools for the physician to simplify the process of reimbursement—with no charge to the physician.

APARAJITA SINGH, MD, MPH
Division of Hospital Medicine
University of California San Francisco

doi:10.3949/ccjm.76c.03003